Donor‐specific HLA antibodies: evaluating the risk for graft loss in renal transplant recipients with isotype switch from complement fixing IgG1/IgG3 to noncomplement fixing IgG2/IgG4 anti‐HLA alloantibodies

Human leukocyte antigen alloantibodies have a multitude of damaging effects on the allograft, both complement (C′) activation and Fc‐independent ones. To date, the clinical significance of non‐C′ fixing (NCF) HLA donor‐specific antibodies (DSA) is still unclear. In this study, we investigated whether renal transplant recipients with NCF‐DSA subclasses (IgG2/IgG4, IgA1/IgA2) are at higher risk of graft loss compared to patients with exclusively C′ fixing (IgG1/IgG3). Blood samples from 274 patients were analyzed for HLA IgG and IgA subclasses using a modified single‐antigen bead assay. We identified 50 (18.2%) patients with circulating NCF antibodies either DSA (n = 17) or against third‐party HLA (n = 33). NCF‐DSAs were preferentially of IgG2/IgG4 isotype (11/17) and were mainly directed against HLA class II (13/17). NCF DSA were present as a mixture with strong C′ fixing IgG1/IgG3. Graft survival was similar between patients with exclusively C′ fixing antibodies and those with a mixture panel (log rang test P = 0.162), and also among patients with different immunoglobulin isotype and subclasses (long‐rank test, P = 0.732). We conclude that expansion of DSA to NCF subclasses postrenal transplantation does not seem to be associated with worse graft survival as compared to the presence of exclusive C′ fixing subclasses.

[1]  S. Sutherland,et al.  Complement‐fixing donor‐specific antibodies identified by a novel C1q assay are associated with allograft loss , 2012, Pediatric transplantation.

[2]  S. Tangye,et al.  Isotype Switching by Human B Cells Is Division-Associated and Regulated by Cytokines1 , 2002, The Journal of Immunology.

[3]  R. Coffman,et al.  Brief Definitive Report TRANSFORMING GROWTH FACTOR # SPECIFICALLY ENHANCES IgA PRODUCTION BY LIPOPOLYSACCHARIDE-STIMULATED , 2022 .

[4]  F. Heinemann,et al.  Immunoglobulin isotype-specific characterization of anti-human leukocyte antigen antibodies eluted from explanted renal allografts. , 2007, Human immunology.

[5]  E. Reed,et al.  HLA class I antibody-mediated endothelial and smooth muscle cell activation , 2012, Current opinion in organ transplantation.

[6]  S. Busque,et al.  C1q-Fixing Human Leukocyte Antigen Antibodies Are Specific for Predicting Transplant Glomerulopathy and Late Graft Failure After Kidney Transplantation , 2011, Transplantation.

[7]  C. E. Schrader,et al.  Mechanism and regulation of class switch recombination. , 2008, Annual review of immunology.

[8]  A. Lobashevsky,et al.  Subtypes of immunoglobulin (Ig)-G antibodies against donor class II HLA and cross-match results in three kidney transplant candidates. , 2010, Transplant immunology.

[9]  W. Hörl,et al.  Solid phase detection of C4d‐fixing HLA antibodies to predict rejection in high immunological risk kidney transplant recipients , 2013, Transplant international : official journal of the European Society for Organ Transplantation.

[10]  W. Baldwin,et al.  Non‐Complement‐ and Complement‐Activating Antibodies Synergize to Cause Rejection of Cardiac Allografts , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[11]  S. Ohlman,et al.  THE OCCURRENCE OF CYTOTOXIC AND NON‐COMPLEMENT‐FIXING ANTIBODIES IN THE CROSSMATCH SERUM OF PATIENTS WITH EARLY ACUTE REJECTION EPISODES , 1992, Transplantation.

[12]  G. Klintmalm,et al.  Donor‐specific human leukocyte antigen antibodies of the immunoglobulin G3 subclass are associated with Chronic rejection and graft loss after liver transplantation , 2012, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[13]  G. Vidarsson,et al.  Chimeric IgA antibodies against HLA class II effectively trigger lymphoma cell killing. , 2002, Blood.

[14]  I. Doxiadis,et al.  16th IHIW: Anti‐HLA alloantibodies of the of IgA isotype in re‐transplant candidates , 2012, International journal of immunogenetics.

[15]  F. Christiansen,et al.  14th International HLA and Immunogenetics Workshop Prospective Chronic Rejection Project: a three-year follow-up analysis. , 2007, Clinical transplants.

[16]  N. Banner,et al.  C4d Fixing, Luminex Binding Antibodies—A New Tool for Prediction of Graft Failure After Heart Transplantation , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[17]  J. Boletis,et al.  Long‐term follow up for anti‐HLA donor specific antibodies postrenal transplantation: high immunogenicity of HLA class II graft molecules , 2011, Transplant international : official journal of the European Society for Organ Transplantation.

[18]  Zu-hua Gao,et al.  Immunoglobulin‐G subclass antidonor reactivity in transplant recipients , 2004, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[19]  I. Doxiadis,et al.  Prevalence and specificity of immunoglobulin G and immunoglobulin A non-complement-binding anti-HLA alloantibodies in retransplant candidates. , 2008, Tissue antigens.

[20]  G. Böhmig,et al.  Clinical relevance of preformed C4d‐fixing and non‐C4d‐fixing HLA single antigen reactivity in renal allograft recipients , 2009, Transplant international : official journal of the European Society for Organ Transplantation.

[21]  E. Reed,et al.  The link between major histocompatibility complex antibodies and cell proliferation. , 2011, Transplantation reviews.

[22]  A. Warrens,et al.  SKEWING OF PRETRANSPLANT ANTI-HLA CLASS I ANTIBODIES OF IMMUNOGLOBULIN G ISOTYPE SOLELY TOWARD IMMUNOGLOBULIN G1 SUBCLASS IS ASSOCIATED WITH POORER RENAL ALLOGRAFT SURVIVAL , 2004, Transplantation.

[23]  S. Schaub,et al.  Pretransplant IgG Subclasses of Donor-Specific Human Leukocyte Antigen Antibodies and Development of Antibody-Mediated Rejection , 2011, Transplantation.

[24]  R. Colvin.  Antibody-mediated renal allograft rejection: diagnosis and pathogenesis. , 2007, Journal of the American Society of Nephrology : JASN.

[25]  M. Verhaar,et al.  Pretransplant Donor‐Specific HLA Class‐I and ‐II Antibodies Are Associated With an Increased Risk for Kidney Graft Failure , 2012, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[26]  J. R. Machado,et al.  Distinct expression of interleukin 17, tumor necrosis factor α, transforming growth factor β, and forkhead box P3 in acute rejection after kidney transplantation. , 2013, Annals of diagnostic pathology.

[27]  I. Doxiadis,et al.  Detection and specification of noncomplement binding anti-HLA alloantibodies. , 2004, Human immunology.

[28]  G. Böhmig,et al.  C4d-Fixing Capability of Low-Level Donor-Specific HLA Antibodies Is Not Predictive for Early Antibody-Mediated Rejection , 2010, Transplantation.